This November, I AM ALS, a nonprofit dedicated to helping people — both patients and family members — affected…
Articles by Patricia Inácio, PhD
A database integrating long-term respiratory data with natural history data from people with amyotrophic lateral sclerosis (ALS) has been…
A treatment candidate from Revalesio named RNS60 protected motor neurons from damage in a mouse model of amyotrophic…
Modality.AI is teaming up with Target ALS on a clinical study of artificial intelligence (AI) as way to…
A short course of treatment with Revalesio‘s RNS60 as an add-on to standard amyotrophic…
RAG-17, an investigational therapy from Ractigen Therapeutics, was safe and well tolerated across all tested doses in people with…
NRG Therapeutics has received a grant from the nonprofit Target ALS to advance preclinical studies of its new…
Targeting two particular proteins, called H1.2 and PARP1, may lessen the severity of amyotrophic lateral sclerosis (ALS) linked to mutations…
The Muscular Dystrophy Association (MDA) and the International Association of Fire Fighters (IAFF) are teaming up once again, launching more…
Athira Pharma has completed enrollment of the first group of healthy volunteers who’ll receive a single dose of ATH-1105…